Award winning executive search to the private, and investor backed health, care, and life sciences sectors

Health Tech Round Table: A discussion around the challenges and opportunities within HealthTech domestically and globally

December 4, 2024

The forward-thinking CFO: Leadership in the ever-changing Healthcare sector.

October 16, 2024

What is the next big innovation coming to the Life Sciences sector?

Trusted executive search partner to the investment community delivering outstanding leaders for the healthcare and life sciences sectors

Mandates delivered to date

0 %

Delivery rate of all retained mandates

0 %

C-suite appointments are women

0 +

Sub-sectors in healthcare and life sciences supported

Healthcare news, data and analysis
Via Investors in Healthcare

Paolo Pieri has left his role as CEO at Circle Health Group, the UK’s largest private hospital group. Karen Prins, currently COO at the firm, is stepping into the CEO […]

UK: Karen Prins steps into interim CEO role at Circle Health Group following departure of Paolo Pieri

March 20, 2025

Healthcare Hospitals and Clinics People Circle Health Group Karen Prins

Johan Löf, CEO and founder of Sweden-based medtech company Raysearch Laboratories has sold 2 million class B shares, corresponding to 5.8% of the company’s share capital, at SEK250 per share […]

Sweden: Raysearch founder raises SEK500m from sale of company shares

March 20, 2025

Life Sciences Medtech – Healthcare IT News Public Equity Baker & McKenzie

UK pharma, Pfizer, has received gross proceeds of approximately £2.5bn (US$3.3bn) from the sale of its entire remaining shareholding in British healthcare company, Haleon, of approximately 662 million ordinary shares, representing […]

UK: Pfizer raises £2.5bn from disposal of last holding in Haleon

March 20, 2025

Consumer Healthcare Healthcare News Public Equity Barclays

British Patient Capital, a commercial subsidiary of the British Business Bank, has made a £25m (US$32m) commitment to the Dementia Discovery Fund 2 (DDF-2), managed by SV Health Investors. Including […]

UK: SV Health Investors’ Dementia Discovery Fund 2 (DDF-2) secures £25m commitment from British Patient Capital

March 20, 2025

Healthcare Mental Health News Venture British Patient Capital

Maxion Therapeutics, a biotech company developing antibody-based ‘KnotBody’ drugs for ion channel- and G protein coupled receptor (GPCR)-driven diseases, has raised US$72m (£58m) in a Series A financing led by […]

UK: Maxion Therapeutics raises US$72m in Series A financing

March 19, 2025

Manufacturing – Specialty Pharma News Pharma Venture Arndt Schottelius

Diaverum, a Sweden-born, multinational healthcare organisation providing life-enhancing renal care to patients with chronic kidney disease, is expanding in Germany with the acquisition of two new clinics, bringing its current […]

Germany: Diaverum expands in Germany with acquisition of two new clinics

March 19, 2025

Healthcare Hospitals and Clinics M&A News Diaverum

Healthcare Holding Schweiz, a distributor of medical devices and services across the Swiss healthcare landscape managed by multi-family investor Winterberg Advisory, has acquired Effectum CH-Rep. Through this acquisition, Healthcare Holding Schweiz strengthens its position […]

Switzerland: Healthcare Holding Schweiz adds Effectum CH-Rep to growing portfolio

March 19, 2025

Buy Out Life Sciences M&A Medtech – Hospital Equipment Medtech – Medical Devices and Implants

AstraZeneca has entered into a definitive agreement to acquire EsoBiotec, a Belgium-based biotech company pioneering in vivo cell therapies. The acquisition includes EsoBiotec’s Engineered NanoBody Lentiviral (ENaBL) platform, which empowers the […]

Belgium: AstraZeneca advances cell therapy ambition with US$1bn acquisition of EsoBiotec

March 18, 2025

IVD – Tools Life Sciences M&A News AstraZeneca

Asker Healthcare, a Sweden-based provider of medical products and solutions, has set the final price in its upcoming IPO at SEK70 per share, equivalent to a valuation of approximately SEK26.8bn. The […]

Sweden: Asker sets final price for IPO

March 18, 2025

Life Sciences Medtech – Hospital Equipment Medtech – Medical Devices and Implants News Public Equity

Sofinnova Partners, a European life sciences venture capital firm based in Paris, London, and Milan, has held the final close of Sofinnova Biovelocita II, a biotech acceleration fund. Biovelocita II […]

France: Sofinnova Partners exceeds target with close of €165m biotech acceleration fund

March 18, 2025

Manufacturing – Specialty Pharma News Pharma Venture Alex Leech

Sanoptis, a Switzerland-based European network of modern ophthalmology clinics, has secured a €250m (US$274m) capital increase in the form of preferred equity from US-based PE investors Carlyle. Funding will support […]

Switzerland: Sanoptis secures €250m in growth capital from Carlyle

March 18, 2025

Healthcare News Ophthalmology Venture Carlyle

DocMorris, a Swiss online pharmacy and pharma wholesaling group, is evaluating various options for raising equity of around CHF200m (US$227m), to strengthen its balance sheet in order to support strategic […]

Switzerland: DocMorris evaluating options to raise CHF200m of equity

March 17, 2025

Consumer Healthcare Debt Healthcare News Pharmacy

Taiho Pharmaceutical, a subsidiary of Tokyo-listed Otsuka Holdings, is acquiring Switzerland-based Araris Biotech, a company developing next-generation antibody drug conjugates (ADCs). Under the terms of the agreement, Taiho Pharmaceutical will pay […]

Switzerland: Taiho Pharma paying up to US$740m for ADC developer Araris Biotech

March 17, 2025

M&A Manufacturing – Specialty Pharma News Pharma 4BIO Capital

SIX-listed pure-play dermatology company, Galderma, has issued three bonds as part of its refinancing strategy to spread out its maturity profile, diversify funding sources and reduce its interest costs. It […]

Switzerland: Galderma launches inaugural euro-denominated bond and returns to Swiss francs

March 17, 2025

Consumer Healthcare Debt Healthcare News BNP Paribas

DBay Advisor’s planned acquisition of listed UK consumer healthcare company Alliance Pharma has received the necessary shareholder approval. In January, the board of Alliance Pharma agreed terms on a proposed […]

UK: DBay £362m acquisition of Alliance Pharma receives shareholder approval

March 17, 2025

Buy Out Consumer Healthcare Healthcare M&A Manufacturing – Generics

Czech Republic-based EMMA Capital Group has become the majority owner of Diamedix, one of Romania’s largest independent medical equipment distributors, from Spanish private equity group Buenavista Equity Partners, which held […]

Romania: EMMA Capital Group acquires Diamedix

March 14, 2025

Buy Out Diagnostics Healthcare M&A News

Ireland domiciled US pharmas Mallinckrodt and Endo have entered into a definitive agreement to combine in a stock and cash transaction to create a global, scaled, diversified pharmaceuticals leader. Endo shareholders […]

Ireland: Mallinckrodt and Endo agree US$6.7bn merger

March 14, 2025

M&A Manufacturing – Specialty Pharma News Pharma Public Equity

Germany-based MEDICE – The Health Family, a European pharmaceutical company focused on the treatment of ADHD, has acquired Selfapy, a Germany-based company offers scientifically proven online psychotherapy courses. With the […]

Germany: MEDICE – The Health Family acquires Selfapy to become a leading provider of mental health therapies

March 14, 2025

Digital Health/Healthtech Healthcare M&A Mental Health News

Athens-listed Piraeus Financial Holdings’ subsidiary Piraeus Bank has entered into a share purchase agreement to acquire a 90.01% stake in the parent company of Ethniki Insurance from CVC Capital Partners Fund […]

Greece: Piraeus Bank acquire CVC’s 90.01% stake in Ethniki Insurance

March 13, 2025

Healthcare Insurance M&A CVC Ethniki Insurance

CVC Capital, through Theia Holdings, has sold almost half its stake in Synsam, the Nordic region’s leading player in optical retail, eye fashion and eye health, in an accelerated book […]

Sweden: CVC raises SEK922.5m through sale of Synsam shares

March 13, 2025

Consumer Healthcare Cosmetic & Aesthetics Healthcare News Ophthalmology

Ireland-headquartered, Nasdaq-listed Jazz Pharmaceuticals, a global biopharmaceutical company. is acquiring US-based Nasdaq-listed Chimerix, an oncology focused biotech, for US$8.55 per share in cash, representing a total consideration of approximately US$935m. The price represents […]

Ireland: Jazz adds to oncology pipeline with Chimerix

March 13, 2025

M&A Manufacturing – Specialty Pharma News Pharma Public Equity

Belgium-headquartered Plastiflex Group, a manufacturer of high-end tubing systems, has acquired US-based Smooth-Bor Plastics, a healthcare company specialised in the production of corrugated heated tubes for continuous positive airway pressure […]

Belgium: Plastiflex strengthens with acquisitions of Smooth-Bor and TIK

March 12, 2025

Buy Out Life Sciences M&A Medtech – Medical Devices and Implants News

Spanish language newspaper, El Confidential, has reported that CVC is close to the sale of Vitalia Home to US-listed StepStone for more than €600m, quoting sources from the sector confirming […]

Spain: CVC declines to comment on reported impending sale of Vitalia to StepStone

March 12, 2025

Care Homes News Real Estate Social Care CVC

The UK’s health tech sector is made up of a host of small players, but as hospitals and clinics continue to face mounting pressures—from workforce shortages to growing patient demand—and […]

Health Tech M&A – ripe for consolidation in 2025

March 12, 2025

Analysis Digital Health/Healthtech Healthcare 24Haymarket Ananda Impact Ventures

Shareholders in Swiss pure-play dermatology company Galderma have raised CHF1.34bn (US$1.5bn) in a secondary sale this week, say reports. Some 15 million shares were sold at CHF89 per share. The […]

Switzerland: Galderma share sale raises CHF1.34bn despite choppy markets

March 12, 2025

Cosmetic & Aesthetics Healthcare News Public Equity Abu Dhabi Investment Authority

Our Sectors

We are experts at what we do

Healthcare

Social Care

Biopharmaceuticals

Medical Technologies

Enabling Services

01 Our People

A dedicated team of executive search experts, delivering for you

The Compass Carter Osborne team are healthcare and life science experts. As a trusted advisor we bring decades of search experience and an unparalleled track record of delivery across our dedicated sectors for our investor clients – relied upon time and again to build outstanding leadership teams.

Familiar faces at key industry events, our expertise extends beyond the mere placing of people with our consultants bringing together sector leaders to address key challenges, working in partnership to produce tangible solutions.

Our Team

Meet the Team

Adam Carter

Meet the Team

Luke Osborne

Meet the Team

Sam Leighton-Smith BA Hons

02 Expertise

Unearthing rare talent, that drive successful exits

Responsive, adaptable, and emotionally intelligent, Compass Carter Osborne avoid the one-size-fits-all approach to ensure our clients achieve their desired outcome by presenting a broad range of intuitive, tailored solutions, based on specific needs.

Expertise

Board

Expertise

Executive Leadership

Expertise

Finance & Commercial

Expertise

Corporate Services

03 Our Approach

Tailoring our offering,
to provide a bespoke service

Results driven, not process led, CCO avoid the conformity of a rigid process. Never assumptive, we listen and adopt an agreed approach which most closely delivers to a clients specific needs. Understanding the uniqueness of each role, our people tailor a search to bespoke requirements to ensure solutions that delivers the best possible results first time, every time.

Our Approach

A trusted advisor to the investment community
providing leaders advancing the healthcare and life sciences sectors

What our clients say

“Compass Carter Osborne really delivered for us in our search for a new CEO for Outcomes First Group. It was a vitally important assignment given that we were recruiting a successor for a long standing and highly successful CEO in a sector-leading business. Compass Carter Osborne went above and beyond in developing a deep understanding of the business and our requirements, and in only presenting candidates that closely met these. They think very creatively and their focus was very sharp; they particularly understood the culture of the business. The search was speedy and well organised, with a very high standard of verbal and written feedback. They have a granular knowledge of the sector and because of the way in which they work, we were fully involved throughout and achieved a great result. A really excellent search – thank you.”

Outcomes First Group – Chair

“Compass Carter Osborne started from the very beginning with a detailed, professional explanation of the available position. They spent time to present the great opportunity and chance to accelerate my career but at the same time, the challenge, and the strong expectation from their client.”

Hengrui Therapeutics – VP, Head Biological Drug Discovery

“Compass Carter Osborne delivered on a key appointment for the PFA and the wider football industry. It was a complex brief involving creating an entirely new position. The role was vitally important, with the successful candidate taking on a sensitive and multifaceted responsibility across CTE, concussion and brain health in professional football. CCO led a comprehensive and exhaustive process, developing a deep understanding of the union’s requirements and using his expert knowledge to help scope and evolve the brief throughout the search. The entire process was professional, efficient and well organised, with consistent communication and feedback at every stage.”

The Professional Footballers Association (PFA) – Chief Executive Officer

“I have been so impressed by Luke’s integrity, clear purpose and drive to achieve for his clients. Luke has worked with Priory on a number of things but more recently to source two independent Non Executive Directors and a Director of Talent Acquisition. He has kept us informed, fielded some great candidates and follows up at each stage, even when they have started. I would really recommend him if you are searching for high calibre individuals.”

Priory Group – Chief Executive Officer

“I recently had the pleasure of being appointed to an independent healthcare provider as a NED after being put forward for the role by Luke. Throughout the whole recruitment process I was treated with respect and felt valued. I was particularly impressed with the follow up support after the decision to appoint me, which I have never experienced from other search companies. Luke continued to check in with me to ensure my onboarding went smoothly and that I had settled into the role. Overall, a highly professional and comprehensive approach delivered personally by Luke.”

Priory – Independent Non-Executive Director

“Luke was absolutely brilliant along the journey. He acted as a real partner and was able to answer to all my questions in order to get comfortable with the decision of making the change. His expertise and knowledge of the sector really came out along the process. Most importantly, he was always available when I needed him to be, which is something I valued a lot. In summary, I couldn’t recommend him and Compass Carter Osborne enough.”

AniCura – Group Chief Operating Officer

“We worked with Compass Carter Osborne in the search for our Chief Financial Officer and from the start it was clear they were a good choice of partner. A focus on understanding our needs as a business, and mine personally as a CEO were front of mind for Paul and Kieran. They took the time to listen, understand and not only focus on the functional aspects of the role – but critically, the team fit and culture we are building. Process, structure and follow-through were like clockwork, and the quality of candidates were of a consistently high-level. I would highly recommend Compass Carter Osborne.”

Renaiss Health – Chief Executive Officer

“I’ve known Tarquin for over 15 years, during which time he has delivered a number of executive assignments at senior level, including COO/executive team and senior management roles in scientific/professional disciplines (his network in the biotech/life-sciences sector is second-to-none!). He works hard to truly understand both the candidate brief and the culture of the company, sets realistic expectations and retains regular contact as an assignment progresses, always providing thorough updates and pragmatic advice. He has the highest levels of professionalism and integrity – he really is a pleasure to work with.”

One Nucleus – Director

“Jamie did a great job – he really took the time to understand our business, our needs and what we were looking for. We knew our brief was specific, yet Jamie met all our expectations with the search. He maintained a high standard of communication and meticulous attention to detail throughout the process. I would recommend Jamie and the Compass Carter Osborne team without hesitation.”

Melrose Education – Chair & CEO

“Our recent work with Compass Carter Osborne was exceptional. The search was perfectly organised, response times were swift, and due to the consultant market knowledge and network, we quickly found our ideal candidate.”

Schoen Clinic – Member of Group Executive